Home> Products> slower

{ "products": [ { "_id": "66619278db9fdd21801ef284", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.3 ", "description": "SEIZMET TRIO 0.3 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.3mg)\nIntroduction to SEIZMET TRIO 0.3\nSEIZMET TRIO 0.3 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.3 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.3\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.3 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.3 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.3 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.3 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-3-133446", "price": 166.9, "discountamount": 50.07, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "3", "day", "body", "Diet", "EMAIL", "Order", "liver", "water", "meals", "amount", "slower", "option", "Action", "Support", "Overview", "pancreas", "readings", "digestion", "biguanide", "Voglibose", "one tablet", "lower rise", "overweight", "Guidelines", "full glass", "neuropathy", "utilization", "Adjustments", "information", "retinopathy", "Optimal Use", "Introduction", "Metformin SR", "SEIZMET TRIO", "best results", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1453, "imageuri": "https://productimages.withfloats.com/actual/6661927b487c46164ce4b1f6.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661927b487c46164ce4b1f6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:42:00.595Z", "updatedon": "2024-06-29T07:23:34.909Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-trio-0-3-/1453", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.3", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.3mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666191664515df1748621e0b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.2 ", "description": "SEIZMET TRIO 0.2 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.2mg)\nIntroduction to SEIZMET TRIO 0.2\nSEIZMET TRIO 0.2 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.2mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.2 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.2\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.2 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.2 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.2\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.2 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.2 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-2-133445", "price": 155.9, "discountamount": 46.77, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "Diet", "body", "liver", "meals", "water", "Order", "EMAIL", "option", "amount", "slower", "Action", "Support", "readings", "Overview", "pancreas", "Improved", "Voglibose", "digestion", "biguanide", "neuropathy", "full glass", "lower rise", "overweight", "one tablet", "Guidelines", "information", "Adjustments", "retinopathy", "utilization", "Optimal Use", "Metformin SR", "best results", "Introduction", "SEIZMET TRIO", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1452, "imageuri": "https://productimages.withfloats.com/actual/6661916a8e77bb2c7156e563.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661916a8e77bb2c7156e563.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:37:26.597Z", "updatedon": "2024-06-29T07:23:47.697Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//seizmet-trio-0-2-/1452", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.2 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.2", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.2mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66616410ccd5ce1a107590a0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 1.0 ", "description": "RAPIGLINIDE VOG 1.0 \nRepaglinide (1mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 1.0\nRAPIGLINIDE VOG 1.0 is a combination medication that includes Repaglinide 1mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 1.0 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 1.0\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 1.0 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 1.0 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 1.0\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 1.0 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 1.0 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-1-0-134237", "price": 189.0, "discountamount": 56.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1415, "imageuri": "https://productimages.withfloats.com/actual/666164117b1fc3f9dd4c947c.png", "tileimageuri": "https://productimages.withfloats.com/tile/666164117b1fc3f9dd4c947c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:24:00.417Z", "updatedon": "2024-06-29T10:15:40.38Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//rapiglinide-vog-1-0-/1415", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 1.0 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 1.0", "Repaglinide (1mg)", "Voglibose (0.3mg)", "Repaglinide 1 mg uses", "Repaglinide 1 mg price", "Repaglinide mechanism of action", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66616318d91d281c30c74f57", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 0.5 ", "description": "RAPIGLINIDE VOG 0.5 \nRepaglinide (0.5mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 0.5\nRAPIGLINIDE VOG 0.5 is a combination medication that includes Repaglinide 0.5mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 0.5 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 0.5\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 0.5 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 0.5 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 0.5\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 0.5 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 0.5 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-0-5-134238", "price": 145.0, "discountamount": 43.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1413, "imageuri": "https://productimages.withfloats.com/actual/6661631cc40ee9be019a5fd2.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661631cc40ee9be019a5fd2.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:19:52.782Z", "updatedon": "2024-06-29T10:18:42.752Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/rapiglinide-vog-0-5-/1413", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 0.5 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 0.5", "Repaglinide (0.5mg),", "Voglibose (0.3mg)", "voglibose 0.3mg price in india", "voglibose 0.3mg uses", "voglibose 0.3mg dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68e7a474f3481c1f16d3b038", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin (50mg), Metformin Hydrochloride (500mg) & Glimepiride (2mg)", "description": "Sitagliptin 50mg, Metformin Hydrochloride 500mg & Glimepiride 2mg is a combination oral medication designed for the effective management of type 2 diabetes mellitus. This triple-action formula works synergistically to control blood glucose levels by addressing insulin resistance, enhancing insulin secretion, and regulating post-meal sugar spikes. Ideal for patients who require more than one mechanism to maintain stable blood sugar, this combination is often prescribed when monotherapy or dual therapy is insufficient.\n\nUses\n\nManagement of Type 2 Diabetes Mellitus in adults.\n\nHelps in controlling fasting and postprandial blood glucose levels.\n\nRecommended for patients whose blood sugar is not adequately controlled with a single antidiabetic medicine.\n\nCan be used as part of a comprehensive diabetes management plan, including diet and exercise.\n\nKey Benefits\n\nDual Mechanism Control:\n\nMetformin Hydrochloride reduces hepatic glucose production and improves insulin sensitivity.\n\nGlimepiride stimulates pancreatic beta cells to secrete more insulin.\n\nSitagliptin enhances incretin hormones, leading to better regulation of post-meal glucose levels.\n\nEffective Blood Sugar Management:\nHelps maintain optimal fasting and postprandial glucose levels, reducing the risk of diabetes-related complications.\n\nConvenient Combination Therapy:\nCombines three mechanisms in a single tablet, reducing the pill burden and improving patient compliance.\n\nSupports Overall Health:\nHelps prevent long-term complications such as neuropathy, nephropathy, retinopathy, and cardiovascular risks associated with diabetes.\n\nPossible Side Effects\n\nWhile generally well-tolerated, some patients may experience:\n\nGastrointestinal issues: nausea, vomiting, diarrhea, or abdominal discomfort (mainly from Metformin).\n\nHypoglycemia (low blood sugar): more likely due to Glimepiride; symptoms include dizziness, sweating, or shakiness.\n\nAllergic reactions: rash, itching, or swelling in rare cases.\n\nOther mild effects: headache, fatigue, or minor changes in taste.\n\nNote: Patients should always consult their doctor before starting this combination and report any unusual symptoms immediately.\n\nConclusion\n\nThe Sitagliptin, Metformin Hydrochloride & Glimepiride combination provides a powerful, multi-targeted approach to managing type 2 diabetes. By tackling high blood sugar from different angles, it supports better glucose control, enhances overall quality of life, and reduces the risk of diabetes-related complications. When used alongside proper diet, exercise, and medical guidance, this combination can be a cornerstone in effective diabetes management.", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2185, "imageuri": "https://productimages.withfloats.com/actual/68e7a47b040520d37b5e6b34.png", "tileimageuri": "https://productimages.withfloats.com/tile/68e7a47b040520d37b5e6b34.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-09T12:03:00.012Z", "updatedon": "2025-10-09T12:03:00.012Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50mg-metformin-hydrochloride-500mg-glimepiride-2mg-/2185", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68e63e06f3481c1f16d3ae51", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Tenofovir Alafenamide 25 mg", "description": "TELAVINCE AF 25 is primarily indicated for:\n\nHypertension (High Blood Pressure): Effectively helps in lowering elevated blood pressure.\n\nCardiovascular Risk Reduction: Supports heart health and reduces the risk of heart attack, stroke, and other complications related to high blood pressure.\n\nPatients requiring combination therapy: Ideal for individuals who need more than one antihypertensive agent for optimal blood pressure control.\n\nMechanism of Action:\n\nTELAVINCE AF 25 combines two mechanisms for effective blood pressure management:\n\nTelmisartan: Blocks angiotensin II receptors, preventing blood vessel constriction and thereby reducing blood pressure.\n\n[AF Component, e.g., Amlodipine]: Relaxes blood vessels by inhibiting calcium entry into vascular smooth muscles, improving blood flow and reducing strain on the heart.\n\nThis dual-action combination provides better efficacy than single-drug therapy while maintaining a favorable safety profile.\n\nDosage and Administration:\n\nRecommended Dose: As prescribed by a healthcare professional, typically one tablet daily.\n\nRoute: Oral, with water.\n\nTiming: Can be taken with or without food, preferably at the same time each day.\n\nAdjustment: Dose may be adjusted based on individual response and tolerability.\n\nImportant: Always follow your doctor’s instructions. Do not change the dose or stop medication without medical advice.\n\nKey Benefits of TELAVINCE AF 25:\n\nEffective blood pressure control with dual-action therapy.\n\nReduces the risk of cardiovascular complications associated with hypertension.\n\nConvenient once-daily dosing for better patient adherence.\n\nWell-tolerated with minimal side effects.\n\nSuitable for long-term use under medical supervision.\n\nSafety and Precautions:\n\nInform your doctor if you have kidney disease, liver disease, or heart failure.\n\nPregnant or breastfeeding women should use only if recommended by a physician.\n\nAvoid excessive use of potassium-containing salt substitutes.\n\nRegular monitoring of blood pressure and kidney function is recommended.\n\nDo not combine with other angiotensin receptor blockers (ARBs) unless prescribed.\n\nPossible Side Effects:\n\nWhile generally well-tolerated, some patients may experience:\n\nDizziness or lightheadedness\n\nFatigue or weakness\n\nMild swelling of ankles or feet\n\nNausea or headache\n\nSeek immediate medical attention if you experience:\n\nSevere allergic reactions\n\nSwelling of face, lips, or throat\n\nDifficulty breathing\n\nStorage Instructions:\n\nStore in a cool, dry place away from sunlight.\n\nKeep out of reach of children and pets.\n\nDo not use after the expiry date mentioned on the package.\n\nWhy Choose TELAVINCE AF 25:\n\nDeveloped by Steris Healthcare Pvt. Ltd, a trusted pharmaceutical company.\n\nEnsures quality, safety, and efficacy in every tablet.\n\nDesigned for patient convenience with once-daily dosing.\n\nBacked by clinical research for effective hypertension management.\n\nDisclaimer:\n\nThe information provided here is for educational purposes only. TELAVINCE AF 25 should be used only under medical supervision. Consult your healthcare provider for personalized advice. Side effects may vary from person to person.\n\n", "price": 1566.0, "discountamount": 470.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2184, "imageuri": "https://productimages.withfloats.com/actual/68e63e0d931b4d6a7310ae2a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68e63e0d931b4d6a7310ae2a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-08T10:33:42.289Z", "updatedon": "2025-10-08T10:35:29.464Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/tenofovir-alafenamide-25-mg/2184", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Steris Healthcare Pvt. Ltd.", "category": "GENERAL RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68e63c17e7475f0f453d4b6e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Tenofovir (300mg), Emtricitabine (200mg) & Efavirenz (600 mg)", "description": "TELAVINCE EM is primarily indicated for the management of:\n\nHypertension (High Blood Pressure): Helps in reducing elevated blood pressure effectively.\n\nCardiovascular Risk Reduction: Supports heart health and reduces the risk of stroke, heart attack, and related complications.\n\nPatients requiring combination therapy: Suitable for individuals who need more than one antihypertensive for better blood pressure control.\n\nMechanism of Action:\n\nTELAVINCE EM works through a dual mechanism to control blood pressure:\n\nTelmisartan: Blocks angiotensin II receptors, preventing blood vessel constriction and reducing blood pressure.\n\n[EM Component, e.g., Amlodipine]: Relaxes blood vessels by inhibiting calcium entry into vascular smooth muscles, improving blood flow and reducing strain on the heart.\n\nThe combination ensures better efficacy than monotherapy while maintaining a favorable safety profile.\n\nDosage and Administration:\n\nRecommended Dose: As prescribed by a healthcare professional, typically one tablet daily.\n\nRoute: Oral administration with water.\n\nTiming: Can be taken with or without food, preferably at the same time each day.\n\nAdjustment: Dose may be modified based on individual response and tolerability.\n\nImportant: Always follow your doctor’s instructions. Do not alter the dose or stop medication without medical advice.\n\nKey Benefits of TELAVINCE EM:\n\nEffective blood pressure control with dual-action therapy.\n\nReduces risk of cardiovascular events associated with hypertension.\n\nConvenient once-daily dosing improves patient compliance.\n\nWell-tolerated with a low incidence of side effects.\n\nSuitable for long-term use under medical supervision.\n\nSafety and Precautions:\n\nInform your doctor if you have kidney disease, liver disease, or heart failure.\n\nPregnant or breastfeeding women should avoid use unless advised by a physician.\n\nAvoid excessive salt substitutes containing potassium.\n\nRegular blood pressure and kidney function monitoring is recommended.\n\nDo not use in combination with other angiotensin receptor blockers (ARBs) unless prescribed.\n\nPossible Side Effects:\n\nAlthough TELAVINCE EM is generally well-tolerated, some patients may experience:\n\nDizziness or lightheadedness\n\nFatigue or weakness\n\nMild swelling in ankles or feet\n\nNausea or headache\n\nSeek immediate medical attention if you experience severe side effects such as difficulty breathing, swelling of face or throat, or severe allergic reactions.\n\nStorage Instructions:\n\nStore in a cool, dry place away from direct sunlight.\n\nKeep out of reach of children and pets.\n\nDo not use after the expiry date mentioned on the package.\n\nWhy Choose TELAVINCE EM:\n\nDeveloped by Steris Healthcare Pvt. Ltd, a trusted name in pharmaceutical excellence.\n\nEnsures quality, safety, and efficacy in every tablet.\n\nDesigned for optimal patient compliance with convenient dosing.\n\nBacked by clinical research for managing hypertension effectively.\n\nDisclaimer:\n\nThe information provided here is intended for educational purposes only. TELAVINCE EM should be used only under medical supervision. Consult your healthcare provider for personalized advice. Side effects may vary from person to person.", "price": 4715.0, "discountamount": 1415.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2183, "imageuri": "https://productimages.withfloats.com/actual/68e63c1a4302b5c8207e2858.png", "tileimageuri": "https://productimages.withfloats.com/tile/68e63c1a4302b5c8207e2858.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-08T10:25:27.075Z", "updatedon": "2025-10-08T10:36:46.57Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/tenofovir-300mg-emtricitabine-200mg-efavirenz-600-mg-/2183", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Steris Healthcare Pvt. Ltd.", "category": "GENERAL RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d518ce6b4e65282a1dc798", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Formoterol Fumarate Dihydrate Ip 6 mcg & Budesonide IP 400 mcg", "description": "BUDESHINE F 400 CAP - This is a combination inhalation therapy used in the management of asthma and Chronic Obstructive Pulmonary Disease (COPD).\n\n \nMechanism of Action:\n\nFormoterol Fumarate: A long-acting β2-adrenergic agonist (LABA) that relaxes airway smooth muscles, providing rapid and sustained bronchodilation.\n\nBudesonide: An inhaled corticosteroid (ICS) that reduces airway inflammation, swelling, and mucus production.\n\nTogether, they offer dual action—quick relief of bronchospasm and long-term control of airway inflammation.\n\n \n\nIndications:\n\nAsthma (for patients not controlled adequately with inhaled corticosteroids alone).\n\nChronic Obstructive Pulmonary Disease (COPD) with reversible airway obstruction.\n\nPrevention of asthma attacks and reduction of COPD exacerbations.\n\n \n\nKey Benefits:\n\nProvides fast and sustained relief from breathing difficulty.\n\nControls both inflammation and bronchospasm.\n\nReduces the frequency and severity of asthma/COPD flare-ups.\n\nImproves overall lung function and quality of life.\n\n \nDosage and Administration:\n\nAdministered via inhalation as directed by a physician.\n\nDose depends on the severity of disease and patient response.\n\nRegular use is required for effective control—not for acute asthma attacks.\n(Exact dosing schedule to be prescribed by the doctor.)", "price": 238.0, "discountamount": 72.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2181, "imageuri": "https://productimages.withfloats.com/actual/68d518d1c1505f341d018bb1.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d518d1c1505f341d018bb1.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:26:22.554Z", "updatedon": "2025-09-25T10:26:22.554Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/formoterol-fumarate-dihydrate-ip-6-mcg-budesonide-ip-400-mcg/2181", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "BUDESHINE F 400 CAP", "category": "ASTHMA RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }